Abstract
Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 112-118 |
| Number of pages | 7 |
| Journal | Journal of Clinical Psychopharmacology |
| Volume | 10 |
| Issue number | 2 |
| State | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Psychiatry and Mental health
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder : Results of a double-blind, placebo-controlled trial. / Taylor, C. B.; Hayward, C.; King, R.; Ehlers, A.; Margraf, J.; Maddock, Richard J; Clark, D.; Roth, W. T.; Agras, W. S.
In: Journal of Clinical Psychopharmacology, Vol. 10, No. 2, 1990, p. 112-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder
T2 - Results of a double-blind, placebo-controlled trial
AU - Taylor, C. B.
AU - Hayward, C.
AU - King, R.
AU - Ehlers, A.
AU - Margraf, J.
AU - Maddock, Richard J
AU - Clark, D.
AU - Roth, W. T.
AU - Agras, W. S.
PY - 1990
Y1 - 1990
N2 - Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.
AB - Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.
UR - http://www.scopus.com/inward/record.url?scp=0025237681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025237681&partnerID=8YFLogxK
M3 - Article
C2 - 2187912
AN - SCOPUS:0025237681
VL - 10
SP - 112
EP - 118
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
SN - 0271-0749
IS - 2
ER -